Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Taysha Gene Therapies, Inc.
| Metric | Taysha Gene Therapies, Inc. TSHAHealthcare |
|---|---|
| Quality Score | 62 / 100 |
| Revenue (latest) | $10M |
| Net income (latest) | −$109M |
| Operating margin | −1130.6% |
| Net margin | −1115.3% |
| Return on equity | −44.1% |
| Return on assets | −31.7% |
| Return on capital (ROCE) | −34.9% |
| Debt / equity | 0.39× |
| Revenue growth (YoY) | 17.3% |
| Altman Z″ (distress) | -0.53 |
| Accruals / assets | −4.6% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.